| Schedule of Disaggregation of Revenue by Nature |
The following table provides information regarding total revenues (dollars in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | (unaudited) | | (unaudited) | | | | Net product sales | | | | | | | | | | | | | Qelbree | $ | 90,824 | | | $ | 81,416 | | | $ | 257,906 | | | $ | 223,708 | | | | | | | GOCOVRI | 42,650 | | | 40,849 | | | 115,420 | | | 108,198 | | | | | | | ONAPGO | 17,075 | | | 6,806 | | | 38,996 | | | 8,410 | | | | | | | Trokendi XR | 10,213 | | | 10,043 | | | 28,103 | | | 34,037 | | | | | | | Oxtellar XR | 7,957 | | | 12,016 | | | 24,161 | | | 33,851 | | | | | | | APOKYN | 6,490 | | | 10,387 | | | 20,541 | | | 38,183 | | | | | | Other(a) | 3,367 | | | 7,025 | | | 9,915 | | | 22,138 | | | | | | | Total net product sales | 178,576 | | | 168,542 | | | 495,042 | | | 468,525 | | | | | | Collaboration revenue (ZURZUVAE)(b) | 41,697 | | | 20,164 | | | 104,690 | | | 20,164 | | | | | | | Royalty, licensing, and other revenues | 6,498 | | | 3,397 | | | 53,802 | | | 18,691 | | | | | | | Total revenues | $ | 226,771 | | | $ | 192,103 | | | $ | 653,534 | | | $ | 507,380 | | | | | |
___________________________________________ (a) Includes net product sales of MYOBLOC, XADAGO and Osmolex ER. (b) Includes the Company's proportionate share of net sales of ZURZUVAE.
|